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ABSTRACT

Anxiety and depression are common comorbidities in people with chronic obstructive
pulmonary disease (COPD), contributing to greater morbidity and mortality in an
already vulnerable population. Despite the prevalence, few recommendations exist in
global management guidelines for the detection and treatment of these comorbidities,
reflecting the limited literature available on effective strategies for dealing with mental
health issues in COPD populations. There is promising evidence that cognitive
behavioural therapy (CBT) improves mental health outcomes in people with COPD.
However, investigational studies have commonly reported participants’ lack of
transport, lack of time and illness as barriers to recruitment and successful completion.
This thesis was undertaken in response to a need identified in the literature for an
alternative modality of CBT delivery for people with COPD suffering from psychological
symptomatology. Thus, a novel home-based self-management CBT learning resource in
a DVD format was developed with an accompanying manual. To investigate the
primary aim of this thesis, a randomised controlled trial called the ‘Breathing New Life’
study was conducted to determine the efficacy of CBT to treat anxiety and depression
in people living with COPD via two formats: group therapy with a reduced number of
sessions or this novel home-based self-management DVD resource, compared to usual
care. The secondary aim was to investigate the efficacy of these interventions on
improvement in health-related quality of life (HRQoL).

This thesis is presented as a series of papers (i.e. PhD with publication) from data
collected from the Breathing New Life study (ACTRN12616001039471). Study One
XIV

investigates the risk factors associated with concomitant anxiety and depression and
found younger age and having no previous psychological medical history were risk
factors for psychological symptomatology compared to those without psychological
symptomatology. Study Two investigates the most suitable screening tool for detecting
clinically significant anxiety and depression in COPD populations and found simple
modifications to the commonly used Hospital Anxiety and Depression Scale (HADS)
improved optimal sensitivity and specificity, whilst the Beck Inventories had acceptable
sensitivity and specificity without any modifications. Study Three reports the results
from the randomised controlled trial investigating the efficacy of CBT delivered in the
two different formats. No significant differences over time between those receiving
CBT and usual care for anxiety, depression or HRQoL were found in this COPD cohort.
However, opinions of benefit expressed in Study Four—a qualitative investigation into
the facilitators and barriers COPD participants face when enrolling and completing
CBT—provide support that this population find CBT useful, despite being unable to
detect any measureable difference.

Globally, this thesis adds new knowledge to the body of literature supporting the
importance of early screening and treatment for psychological symptomology in
people living with COPD. Despite the inability of CBT to improve anxiety and
depression, findings from this thesis have important implications towards industry
discussion surrounding routine screening for concomitant anxiety and depression, the
continued use of the HADS and Beck Inventories as appropriate screening tools in
COPD populations and how best to engage and retain COPD participants in CBT.
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CHAPTER ONE

1

INTRODUCTION

1.1

COPD

Chronic obstructive pulmonary disease (COPD) is typically a progressive lung disease
defined by persistent airflow limitation, classically caused by an enhanced chronic
inflammatory response of the respiratory system to noxious particles or gases.
Prolonged exposure to inhaled irritants is the most common cause of developing
COPD, with the primary risk factor being exposure to tobacco smoke. Indoor air
pollution (e.g. fuels used for cooking and heating) and having a genetic predisposition
(most commonly an alpha-1 antitrypsin deficiency) have also been identified as major
risk factors. The characteristic symptoms of COPD include dyspnoea, chronic cough
and sputum production (1). Prolonged exposure to inhaled irritants results in an influx
of inflammatory cells such as neutrophils, macrophages and CD8+ T-lymphocytes
which then initiates an inflammatory cascade that activates the release of cytokines,
including tumour necrosis factor alpha, interferon gamma, interleukins (IL-1, IL-6, IL-8),
C-reactive protein, matrix-metalloproteinases (MMP-6, MMP-9) and fibrinogen (2).
These processes sustain the amplified chronic inflammatory response observed in
COPD which results in a combination of parenchymal tissue damage (emphysema),
mucociliary dysfunction and numerous structural changes in the lung (obstructive
bronchiolitis), propagating airflow limitation (2, 3).
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COPD is a leading cause of morbidity and mortality worldwide; it is currently estimated
that 65 million people suffer from moderate to severe COPD. Although COPD is a
preventable disease, it is predicted to become the third leading cause of death globally
by 2030 (4). In Australia, one in five persons over the age of 45 have COPD and the
latest data available from 2014 estimated 7,025 deaths eventuated as a result of this
comborbidity—making COPD the fifth leading cause of death (5). However, it is often
argued the prevalence of COPD is underestimated for a number of reasons, including:
the slow nature of COPD development delaying diagnosis until people exhibit
moderate symptoms, experience exacerbations or become disabled; misdiagnosis as
asthma; and people mistaking their COPD symptoms as signs of ageing or lack of
fitness (6).

1.2

The problem

Whilst COPD primarily affects the airways and lungs, it also has significant systemic
consequences which affect quality of life and survival (1, 7). People living with COPD
may also suffer from co-morbid cardiovascular disease, osteoporosis, lung cancer,
sleep-related breathing disorders as well as metabolic syndrome and diabetes (1).
These comorbidities may develop independently of a diagnosis of COPD, be related to
the disease via similar risk factors or one disease increases the risk of developing
another. A major non-systemic comorbidity people with COPD may experience is
psychological distress, in particular anxiety disorders and depression—estimated to
occur in 36% and 40% of people with COPD, respectively (8-10). Research indicates
COPD populations are at a higher risk of developing these psychological comorbidities
2

than the general population and those with other chronic diseases such as
cardiovascular disease and renal disease (9, 11-13). People with COPD suffering from
anxiety or depression have poorer outcomes across a number of health domains,
including: increased exacerbation rates (14-16); diminished exercise performance and
functional mobility (11, 14, 17); poorer health-related quality of life (HRQoL) (16-18);
more emergency hospital visits, hospitalisations and lengths of stay as an admitted
patient (11, 16, 19) and greater mortality rates (11, 20, 21). Consequently, people with
COPD that also suffer from anxiety or depression are a greater economic burden than
those that do not have any psychological symptomatology (22-24).

Despite this public health problem, there are few recommendations in the Global
Initiative for Chronic Obstructive Lung Disease (GOLD) management guidelines for the
treatment of these psychological comorbidities, reflecting the limited literature
available on the efficacy of treatment options (1). There is promising evidence to
suggest cognitive behavioural therapy (CBT) improves mental health outcomes in
COPD populations (25-38). CBT is a psychological intervention generally run over 12
weeks, conducted face-to-face individually or in groups which aims to change the
distorted, unrealistic thinking and negative behaviour patterns thought to contribute
to psychological symptomatology (39-42). However, an ongoing problem with CBT
intervention studies in COPD populations are the low recruitment rates of 13–49% (28,
31, 35, 36, 43) and high attrition rates of 27–47% often reported (28, 32, 44). Possible
solutions could be to reduce the number of face-to-face group CBT sessions or to
eliminate the necessity for attending face-to-face sessions. However, there is a need to
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build upon the limited data currently available to establish the effectiveness of homebased, self-management CBT programs for improving anxiety and depression in people
with COPD. Furthermore, as few studies report the reasons why participants drop out
of CBT, an exploration of the facilitators and barriers people with COPD face with this
type of therapy is warranted to help better explain and improve the rate of uptake and
completion of CBT.

The GOLD guidelines also lack clear recommendations on how to identify anxiety and
depression in people with COPD. This has important implications for the timely
identification and treatment required to reduce the additional morbidity and mortality
these comorbidities have on an already vulnerable population. The Hospital Anxiety
and Depression Scale (HADS), the Beck Anxiety Inventory (BAI) and the Beck
Depression Inventory (BDI-II) are commonly used screening tools to assess the
presence of psychological symptomatology in people with COPD. However, the HADS
has only been validated for use in this population in two previous studies (45, 46),
whereas no previous studies have validated the Beck Inventories, prompting the need
for an investigation into the suitability of these measures in COPD populations.

Whilst early detection is vital for early intervention, preventing the onset of anxiety
and depression in people with COPD in the first place is a fundamental public health
approach to reduce the health services required to ameliorate the morbidity and
mortality associated with these comorbidities. This involves reducing exposure to
modifiable risk factors for psychological symptomatology as well as enhancing the
4

protective factors that promote good mental health and wellbeing. Despite the known
benefits of prevention, the GOLD guidelines do not specify any strategies to decrease
the incidence of anxiety and depression in people with COPD.

1.3

Research aims

The research conducted for this thesis aimed to add evidence to each stage of the
conceptual framework (Figure 1.1) used by allied health professionals to improve the
morbidity and mortality associated with anxiety and depression in COPD populations.
This thesis primarily sought to investigate the efficacy of CBT in addition to usual care
for the treatment of anxiety and depression in people living with COPD, compared to
usual care alone (UC). CBT was delivered via a traditional group therapy format (CBT)
with a reduced number of face-to-face sessions relative to previous programs (25, 2734, 44, 47, 48), or a home-based self-management DVD format (DVD), with efficacy of
both assessed by the level of psychological symptomatology. A randomised controlled
trial was conducted (hereafter referred to as the ‘Breathing New Life’ study) to
investigate this primary aim. The secondary aim of this thesis was to investigate the
efficacy of these CBT interventions to improve HRQoL relative to usual care. This thesis
also sought to investigate the risk factors associated with psychological
symptomatology, the most suitable tool(s) for screening anxiety and depression and to
explore participants’ experiences of CBT to understand the enablers and disablers for
people with COPD to successfully enrol and complete a course.
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*Note: investigations conducted in this thesis are outlined in red

Figure 1.1 A conceptual framework (developed by the candidate) for reducing diseaserelated morbidity and mortality

1.4

Thesis outline

This thesis is presented as a series of papers addressing the research aims utilising data
collected from the Breathing New Life study (Clinical Trial Registration Number:
ACTRN12616001039471). Edith Cowan University (ECU) supports the submission of
PhD theses that comprise a series of papers prepared for publication. ECU’s
Requirements of a Thesis with Publication, 2017 guidelines outline that the submitted
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thesis can consist of publications that have already been published, are in the process
of being published, or a combination of these (49). These guidelines also state that the
number of publications submitted will vary between disciplines and projects, but
should be sufficient for the body of work to constitute a substantial and original
contribution to knowledge (49).

This structure has been adopted by the candidate in the submission of this thesis. As
such, while the theory linking the studies/papers should be clear for the examiner,
each study must be stand-alone in content. Consequently, theses submitted as a series
of papers sometimes suffer from repetition of literature and methodology from study
to study.

1.4.1 Study One
Determinants of concomitant anxiety and depression in people with chronic obstructive
pulmonary disease
The primary aims of this study were to investigate the prevalence and determinants of
concomitant anxiety and depression in people diagnosed with COPD. It was predicted
previous risk factors identified separately for anxiety or depression in people with
COPD were also shared risk factors for concomitant anxiety and depression. The risk
factors found for this COPD cohort adds to the limited data available on potential
protective factors to concomitant psychological symptomatology.
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1.4.2 Study Two
Discriminant validity of the Hospital Anxiety and Depression Scale, Beck Depression
Inventory (II) and Beck Anxiety Inventory to confirmed clinical diagnosis of depression
and anxiety in patients with chronic obstructive pulmonary disease
The aims of this study were to investigate the discriminant validity of the Hospital
Anxiety and Depression Scale (HADS) with people diagnosed with COPD, and to
examine the discriminant validity of the Beck Depression Inventory (BDI-II) and Beck
Anxiety Inventory (BAI) as potential alternatives for this population. It was pedicted
the BDI-II and BAI may be better alternatives for screening people with COPD for
psychological symptomology than the HADS. As there are limited data currently
available on the validity of commonly used screening tools for psychological
symptomatology in people with COPD, the information gathered from this research
adds to the body of literature and provides a foundation for recommendations on the
most appropriate tool(s).

1.4.3 Study Three
A randomised controlled trial investigating the efficacy of cognitive behavioural
therapy on the mental health of people with chronic obstructive pulmonary disease: the
‘Breathing New Life’ study
The primary aim of this study was to investigate the efficacy of CBT in addition to usual
care, to reduce anxiety and depression symptomatology in people living with COPD.
CBT was provided via a traditional group therapy format (CBT) with a reduced number
of sessions relative to previous programs, or a home-based self-management DVD
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format (DVD), compared to usual care alone (UC). The secondary aim was to
investigate the subsequent effect of these CBT interventions on HRQoL.

The study hypotheses were:


People with COPD receiving either format of CBT intervention would
demonstrate lower rates of anxiety and depression symptoms after 12 months
compared to participants in the usual care group (UC). Moreover, the DVD
group would have higher compliance rates during the intervention period than
the face-to-face CBT group due to the more convenient nature of the DVD
resource



COPD participants in either CBT interventions would also demonstrate
improvements in HRQoL compared to participants in the UC group

There is currently no consensus which is the most effective treatment for anxiety and
depression in people with COPD. However, there is emerging data on the effectiveness
of home-based self-management programs. This research investigated the efficacy of a
novel self-management CBT resource to treat anxiety and depression, in the hopes
that the DVD could eventually become a stand-alone resource.

1.4.4 Study Four
A qualitative investigation of the facilitators and barriers for people with chronic
obstructive pulmonary disease to participate in cognitive behavioural therapy
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The aim of this study was to investigate the facilitators and barriers to successful
completion of CBT, delivered either as traditional face-to-face group sessions or a
home-based self-management DVD resource. The information gathered from the firstknown qualitative investigation of the enablers and disablers for COPD participants
towards CBT will help future studies optimise development of their CBT interventions
to improve future uptake and retention in order to ultimately improve mental health
outcomes in people with COPD.
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CHAPTER TWO

2

REVIEW OF THE LITERATURE

2.1

Anxiety and depression

Anxiety is an emotion characterised by somatic symptoms of tension and behavioural
disturbances due to the apprehensive anticipation of future danger or misfortune. The
Diagnostic and Statistical Manual of Mental Disorders (5th edition, DSM-V) defines the
types of anxiety disorders as follows: separation anxiety disorder, selective mutism,
specific phobia, social anxiety disorder, panic disorder, panic attack specifier,
agoraphobia, generalised anxiety disorder, substance/medication-induced anxiety
disorder, anxiety disorder due to another medical condition, other specified anxiety
disorder and unspecified anxiety disorder (50). Whilst each specific anxiety disorder
has slightly different symptoms, they all share the common themes of excessive,
irrational fear and dread (50). In Australia, the latest figures from the 2014–2015
National Health Survey report the 12 month prevalence of anxiety-related conditions
to be 11.2% (2.6 million people) (51).

Depression is “the presence of sad, empty or irritable mood, accompanied by somatic
and cognitive changes that significantly affect the individual’s capacity to function”
(p155) (50). The Diagnostic and Statistical Manual of Mental Disorders (5 th edition,
DSM-V) defines the types of depressive disorders as follows: disruptive mood
dysregulation disorder, major depressive disorder, persistent depressive disorder
(dysthymia),

premenstrual

dysphoric

disorder,
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substance/medication-induced

depressive disorder, depressive disorder due to another medical condition, other
specified depressive disorder, and unspecified depressive disorder (50). What differs
amongst the depressive disorders are specifications of duration, timing or presumed
aetiology (50). The Australian 2014–2015 National Health Survey reports the 12 month
prevalence of mood disorders (which includes depression) as 9.3% (2.1 million people)
(51). It is estimated approximately one in twenty Australians (5.1%) have both an
anxiety-related condition and a mood disorder (51).

2.2

Negative impact of anxiety and depression

People with chronic obstructive pulmonary disease (COPD) suffering from anxiety and
depression have poorer health outcomes compared to those without these
psychological comorbidities. Further adding to the debilitating nature of COPD, people
with anxiety and depression symptomatology experience more frequent exacerbations
(14-16); reduced functional mobility and exercise performance (e.g. less laps achieved
during the six-minute walk distance test) (11, 14, 17); poorer health-related quality of
life (HRQoL) (16-18); increased hospital emergency department visits, increased
hospital admissions and increased lengths of hospital stays (11, 16, 19); and greater
mortality rates (11, 20, 21). In addition, people with COPD that suffer from
psychological symptomatology are also a greater economic burden through increased
expenditure to health and welfare systems, and lost productivity due to lower
employment, absenteeism and premature death (22-24). Early detection of anxiety
and depression in people with COPD is essential in order to appropriately manage the
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comorbidities at the earliest possible stages to reduce the already high rates of
morbidity and mortality in people with COPD.

2.3

Risk factors

Several risk factors have been identified to increase the likelihood of developing
anxiety or depression symptomatology in people with COPD. Shared risk factors for
either anxiety or depression commonly reported in the literature include severe
dyspnoea, poor HRQoL, smoking, lower education levels, lower socioeconomic status
and having other non-psychological comorbidities (52-55). Other determinants
commonly but inconsistently reported include age (some studies suggesting younger
COPD populations, whilst others suggest older COPD populations are at greater risk),
being female, having lower values for forced expiratory volume (FEV1) and greater
severity of COPD (52-54, 56-59). Unique determinants associated with depression
include living alone and not being married (53, 54). There appear to be no unique risk
factors that contribute to people with COPD having anxiety symptomatology alone.
However, there are limited data available on risk factors associated with concomitant
anxiety and depression in people with COPD. It would be reasonable to assume that
the majority of the risk factors identified in the literature for anxiety or depression are
also shared risk factors for concomitant anxiety and depression but this remains to be
determined.
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2.4

Prevalence

The estimated prevalence of anxiety and depression in people with COPD varies
greatly, with estimates for anxiety ranging anywhere from 2–96% and from 8–88% for
depression (9, 60-63). A meta-analysis of reported prevalence of anxiety disorders and
depression in COPD patients, conducted by Yohannes et al. (2010) calculated a
standard measure of effect size for n=13 previous studies and used weighted pooled
estimates to suggest a mean prevalence of 36% for anxiety and 40% for depression can
be used as a clinical benchmark of prevalence estimates in people with COPD (10). The
majority of studies included in the meta-analysis used self-report screening tools
rather than diagnostic clinical interviews.

Another systematic review (n=10 included studies) reported the prevalence of clinical
anxiety to be 10–55% amongst COPD in-patients and 13–46% amongst out-patients
(62). The greatest strength of this review is that all the included studies diagnosed
anxiety disorders via a clinical interview using a recognised, industry standard format
(DSM-IV or previous versions or International Classification of Disease and Related
Health Problems, 10th edition (ICD-10)). For depression, a systematic review found that
those with COPD had a higher prevalence of depressive symptoms than healthy
controls; 24.6% (95% CI: 20.0–28.6%) in COPD patients compared to 11.7% (95% CI:
9.0–15.1%) in controls (63). The strength of this review was that a comprehensive
meta-regression analysis and subgroup effect size analysis was performed to
determine the prevalence of depression. However, limitations of this review include
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the fact that depression was assessed by a variety of measures rather than via
diagnostic clinical interviews, and the number of studies included was small (n=8).

The large variation in data may be attributed to a number of methodological
discrepancies. Method of psychiatric diagnoses vary greatly, with the majority of
studies utilising self-report questionnaires as opposed to diagnostic clinical interviews.
An overlap between somatic symptoms of anxiety and depression with those of COPD
also complicates diagnoses. Screening measures used to detect depression in the
elderly may be less precise due to the overlap of somatic symptoms and those that
occur due to the ageing process. Furthermore, differing degrees of COPD severity,
differing study settings (e.g. clinical populations vs. community based patients) and
sample sizes all contribute to the variations in prevalence figures.

In Australia, there is a paucity of data available on the prevalence of anxiety and
depression in people with COPD. To date, only three published studies have
investigated the prevalence of these comorbidities. The first, by Livermore et al. (2010)
reports that 19% of participants (n=10 out of 52) were clinically diagnosed with panic
attacks, 17% of participants (n=9 out of 52) with panic disorder and 4% with major
depression using the Anxiety Disorders Interview Schedule of the DSM-IV (ADIS-IV)
(33). Panic attacks and panic disorder fall under the larger umbrella of anxiety
disorders, but do not represent all other types of anxiety disorders in Australia. The
second study by Doyle et al. (2013) screened for anxiety and depression using the selfreport Hospital Anxiety and Depression Scale (HADS) and found 27.2% of participants
15

reported symptoms for anxiety and 20.4% reported symptoms for depression (64). The
last study by Walters et al. (2013) also utilised the HADS and found 40% of participants
reported symptoms of anxiety and 20% reported symptoms of depression (36).
Although there are large variations in the prevalence of anxiety and depression in all
three studies, these Australian rates fall within the scope of other international
estimates (9, 60-63).

2.5

Screening for anxiety and depression

A wide range of measures have been reported in the literature for detecting the
presence of anxiety or depression in people with COPD (Table 2.1). The majority of
these measures are self-report screening tools which identify the presence of clinically
significant levels of anxiety or depression symptomatology. A clinical diagnosis of
anxiety or depression is determined via a structured clinical interview which meets The
Diagnostic and Statistical Manual of Mental Disorders or the International
Classification of Diseases and Related Health Problems criteria. The distinction
between the types of measures used in the literature is important, as the majority of
studies examining the prevalence of anxiety and depression in people with COPD have
utilised self-report measures which indicate rates of clinically significant distress levels
rather than provide an actual clinical diagnosis through a psychologist or psychiatrist.
Benefits of using self-report questionnaires include the low costs involved, the
relatively short time it takes to complete, either patients or health service providers
can complete the questionnaires, the questionnaires are extremely easy to administer,
and they can be adapted and validated for specific populations. However, a
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disadvantage of using self-report measures is the potential for inflated misdiagnosis
due to the overlap of somatic symptoms typical of COPD with those of anxiety or
depression. Narrow time-frames for reporting of symptoms (e.g. over the past week or
two weeks) are also a limitation of these types of measures as psychological conditions
can be missed.

The current Global Initiative for Chronic Obstructive Lung Disease (GOLD) management
guidelines lack recommendations for the screening and treatment of psychological
comorbidities in people with COPD (1). Consequently, screening for mental health
symptomatology in COPD populations has not become standard practice and there is a
lack of consensus with respect to the most appropriate tool/s for measurement of
these symptoms. This is likely to result in a lack of timely and effective treatment for
those suffering from these comorbidities. The GOLD guidelines do acknowledge the
“Hospital Anxiety and Depression Scale (HADS) and the Primary Care Evaluation of
Mental Disorders (PRIME-MD) Patient Questionnaire [screening tools] have been used
to improve identification and treatment of anxious and depressed patients” (p90) (1).
Indeed the HADS is one of the most commonly cited screening tools used in COPD
studies (11, 16, 19, 41, 45-47, 56, 65-74) but only two published papers have
established its validity for use in this population (45, 46). The Beck Anxiety Inventory
(BAI) and Beck Depression Inventory (BDI-II) are also popular screening tools
commonly used in the literature to measure anxiety or depression respectively (26-28,
31, 32, 37, 48).
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Table 2.1 Diagnostic and screening measures used to detect anxiety and depression in
people with COPD
Structured Clinical Interviews
Anxiety Disorders Interview Schedule (ADIS)
Composite International Diagnostic Interview (CIDI)
Diagnostic Interview for Psychiatric Disorders (DIPS)
Geriatric Mental State Schedule (GMS)
International Statistical Classification of Diseases and Health Related Problems (ICD)
Mini International Neuropsychiatric Interview (MINI)
Structured Clinical Interview for DSM Disorders (SCID)
World Mental Health Composite International Diagnostic Interview (WMH-CIDI)
Screening Measures
Anxiety and Depression
Edmonton Symptom Assessment Scale (ESAS)
Geriatric Mental State Schedule
Hospital Anxiety and Depression Scale (HADS)
Kellner’s Symptom Questionnaire (SQ)
Primary Care Evaluation of Mental Disorders (PRIME-MD)
Profile of Mood States (POMS)
Symptom Checklist-90-R (SCL-90-R)
Anxiety
Beck Anxiety Inventory (BAI)
Geriatric Anxiety Inventory (GAI)
Manifest Anxiety Scale (MAS)
Spielberger State Trait Anxiety Inventory (STAI)
Depression
Beck Depression Inventory (BDI-II)
Brief Assessment Schedule for Depression Cards (BASDEC)
Centre for Epidemiologic Studies Depression Scale (CES-D)
Geriatric Depression Scale (GDS)
Montgomery–Åsberg Depression Rating Scale (MADRS)
Zung Self-Rating Depression Scale (ZDS)
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2.6

Mechanisms

The mechanism(s) that lead to anxiety and depression in people with COPD are still
largely unknown and poorly understood. It is unclear whether the onset of
psychological symptomatology is a result of the disease itself or due to pre-existing
mental health conditions prior to developing COPD. Several theoretical models have
been proposed for the development of anxiety and depression disorders in the general
population and these have also been applied in COPD populations which are
summarised below.

2.6.1 Mechanisms for anxiety
As dyspnoea and hyperventilation are recurrent symptoms commonly suffered by both
people with COPD and panic anxiety, a number of models have been suggested to
explain the possible shared pathophysiology. These models arise from the literature
surrounding mechanisms for anxiety in people with COPD which mainly describes
panic anxiety; the literature surrounding mechanisms for other anxiety conditions is
presently lacking.

2.6.1.1 The hyperventilation model
The hyperventilation model assumes that panic, anxiety and dyspnoea arise from the
same clinical presentation, i.e. the hyperventilation syndrome whereby symptoms
such as dyspnoea, heart palpitations and chest pain exist but there are no other
causes. People with COPD and anxiety generally have dysfunctional ventilator patterns
which may be connected with hyperventilation. The resultant hypocapnic alkalosis
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may then be responsible for certain symptoms of anxiety and dyspnoea, thereby
producing an exacerbated response (75).

2.6.1.2 The carbon dioxide hypersensitivity model
The carbon dioxide hypersensitivity model is based on the idea that people with COPD
suffering from panic disorder have an abnormally sensitive brainstem respiratory
control mechanism. The pathophysiological mechanism is unclear but it is theorised
that in response to increased carbon dioxide or lactate, abnormally sensitive brainstem
chemoreceptors elicit a ‘suffocation false alarm’ when impending challenges to
suffocation occurs, provoking hyperventilation and a fear of dyspnoea leading to a
panic attack (76). It is proposed that both carbon dioxide and lactate share
mechanisms of action, suggesting a physiological and neuroanatomical overlap.

2.6.1.3 The cognitive behavioural model
The cognitive behavioural model (also known as ‘Clark’s cognitive model’ or the
‘dyspnoea-fear theory’) is the most widely accepted theory for the occurrence of panic
attacks and panic disorder in physically healthy adults. The model is based on the idea
that fear and misinterpretation of physical experiences induced by dyspnoea and
hyperventilation catalyses a panic reaction (77). The cognitive behavioural model has
also emerged as the most widely accepted theory for the onset of anxiety in people
with COPD, as somatic symptoms of anxiety are similar to those associated with the
lung disease. It is hypothesised that people with COPD misconstrue the severity of
their dyspnoea through catastrophic cognitions. This fear of severe breathlessness
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leads to a heightened state of psychological arousal, resulting in further
misinterpretation of increased dyspnoea and worsening of breathlessness due to
hyperventilatory panic attacks, i.e. a positive feedback loop is created (78). It has been
hypothesised that people with COPD with regular catastrophic thoughts about
symptoms have an increased risk of anxiety compared to those who do not have these
regular invasive thoughts (41, 42, 79, 80).

2.6.1.4 The stress model
The most recent theory which has emerged explores the relationship between stress
and anxiety. Pate and Davenport (2013) propose the notion of constant tracheal
occlusion stimulating the persistent release of the stress hormone cortisone which
promotes anxiety (81). Supporting evidence for this proposal comes from the measure
of cortisone in mice where the trachea was occluded. This study found that when mice
were tracheal occluded to mimic the recurrent airway obstruction experienced by
people with COPD, they had a higher release of cortisone. Therefore, it is hypothesised
that people with COPD experience both a psychological and a systemic stress.

2.6.1.5 Smoking
The relationship between smoking and nicotine use in people with COPD and anxiety is
complex, with both anxiogenic and anxiolytic effects being found (60, 82). Support for
this complex pathogenesis comes from studies of general population smokers who
have higher lifetime prevalence rates of anxiety disorders and those with a history of
anxiety disorders reporting more severe nicotine withdrawal symptoms (83, 84). These
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results suggest nicotine may induce anxiety or people with COPD susceptible to anxiety
use nicotine for its sedative effect during heightened states of psychological arousal.
Furthermore, nicotine withdrawal may mimic anxiety symptomatology and people
with COPD smoke to help alleviate these feelings.

2.6.2 Mechanisms for depression
The pathogenetic mechanisms of comorbid depression in COPD are also poorly
understood. Three prevailing biological factors have been put forward as the causes of
depression in people with COPD: smoking, hypoxia and exacerbation of COPD (59, 60,
85, 86). The impact of illness on patients’ lives has also been theorised as a
contributing factor to the onset of depression. These theories are briefly described
below.

2.6.2.1 Biological mechanisms
Smoking is a risk factor for depression in people with COPD, with depression playing a
role in the initiation and maintenance of smoking, smoking being the primary risk
factor for developing COPD, and COPD in turn contributing to the aetiology of
depression (86). However, smoking also appears to play a complex pathogenic role via
the hypoxia generated as a result of smoking. Hypoxia is a consequence of both
smoking and COPD and known to induce neuropsychiatric disturbances such as
psychomotor slowing, memory impairment and depressed mood (56). Various
pathogenetic mechanisms have been suggested, including vascular endothelial
damage, direct damage of white matter in the brain and oxidative stress (56).
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Inflammatory biomarkers have also been postulated to contribute to the onset of
depressive symptomatology in people with COPD due to the link between the
characteristic chronic inflammation of the respiratory system and exacerbations seen
in this disease. People with COPD and depression suffer from increased exacerbation
rates (14-16) and support for the shared inflammation pathway theory comes from
findings of depression being associated with impaired immune function (87-89),
increasing susceptibility to infections (90) and thus infective exacerbations in COPD
populations (91, 92).

2.6.2.2 Impact of COPD
The impact of a chronic illness on peoples’ lives has been theorised as a complex
contributing factor to the onset of depression. Norwood (2007) summarises this
complex relationship into three domains: loss of functionality, increased burden on
internal coping mechanisms and perceived social support (86). People with COPD may
experience a lack of mobility, an inability to physically perform previous occupational
activities or participate in recreational activities, and may require the use of oxygen
therapy. Norwood states “the psychological losses attached to each of these insults are
first the loss of the phenomenon itself and secondly of the emotion or material
benefits derived from it” (p486) (86). Poor coping and low self-efficacy skills that
accompany the grief and functional loss with COPD have been proposed to decrease
the sense of self-mastery a person requires to optimally adjust to living with the
disease and thus increases the likelihood of depressive symptomatology. Finally,
Norwood proposes the level of social support that a person with COPD perceives (e.g.
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social inclusion, marital status, having a carer) contributes to their resilience to
depression (86).

2.7

Treatment of anxiety and depression in people with COPD

Despite anxiety and depression being major comorbidities in people with COPD, there
are no standardised guidelines—either internationally or in Australia—for their
treatment. The lack of research on the effectiveness of pharmacological and nonpharmacological therapies used to treat anxiety and depression in COPD has
contributed to the absence of clear recommendations for treatment in global
guidelines. The only advice given in the recently updated GOLD guidelines published in
2017 is that: “there is no evidence that anxiety and depression should be treated
differently in the presence of COPD” (p117) (1). The current Australian and New
Zealand COPD management guidelines merely state that there is “promising evidence”
for the use of cognitive behavioural therapy (CBT) and medication prescribed by
psychiatrists and psychologists for treating anxiety and depression symptomatology
(93). With no standard procedures in place for the treatment of anxiety or depression
in this population, the current management of these comorbidities is largely
dependent on the discretion of the treating physician (Prof. Grant Waterer, personal
communication with Dr. Natalie Strobel, 17 Feb 2012). In the general population, these
psychological comorbidities are treated with either pharmacotherapy, psychotherapy
or a combination of these two—with treatment being dependent on the severity of
the psychological disorder and personal preference. These treatment options have also
been applied in people with COPD, as well as the use of pulmonary rehabilitation and
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relaxation therapy to manage anxiety disorders and depression, with mixed effects.
The following section aims to summarise the treatment methods and the evidence
surrounding their application in people with COPD.

2.7.1 Pharmacotherapy
Pharmacological interventions have long been used in standard clinical practice to
treat anxiety and depression in the general population. The principal medications used
to control symptoms include antidepressants (selective serotonin re-uptake inhibitors,
tricyclic antidepressants and monoamine oxidase inhibitors), benzodiazepines,
azapirones and less commonly, antipsychotic agents and anticonvulsants (94). Some of
these medications have also been commonly applied in people with COPD, despite the
lack of quality studies to assess their efficacy in this population. Of the few studies
which have been conducted to determine the effects of pharmacological treatment of
anxiety and depression in people with COPD, evidence remains equivocal. These
studies have typically been fraught with differing sample sizes, large dropout rates
and/or short follow-up periods. A Cochrane review conducted by Usmani et al. (2006)
on the various pharmacological interventions used was unable to conclude on effective
treatment options due to the sub-optimal quality of the research, noting the included
studies (n=4) had small sample sizes, short follow-up periods and non-statistically
significant results (95). Their review highlights the paucity of data with respect to
quality randomised controlled trials. Previous researchers have identified numerous
problems with the use of pharmacotherapy for the treatment of anxiety and
depression in people with COPD, including: adverse side effects, misapprehension
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about being stigmatised, non-compliant use of medication, negative previous
experiences with pharmacotherapy, mistrusting the psychiatrist and side effects
aggravating other comorbidities (96). Despite the lack of published evidence on the
effectiveness of pharmacotherapy to treat anxiety disorders and depression in this
population, it remains a common treatment option selected by treating physicians
(Prof. Grant Waterer, personal communication with Dr. Natalie Strobel, 17 Feb 2012).

2.7.2 Pulmonary rehabilitation
Pulmonary rehabilitation is an “evidence-based, multidisciplinary, and comprehensive
intervention for patients with chronic respiratory diseases who are symptomatic and
often have decreased daily life activities” (p2) (97). The objective of pulmonary
rehabilitation is to “reduce symptoms, optimize functional status, increase
participation, and reduce health care costs” through exercise training, education,
nutritional intervention and psychosocial support (p2) (97). There is an emerging body
of literature on the effect of pulmonary rehabilitation to reduce symptoms of anxiety
and depression in people with COPD (1, 98).

In the most recent meta-analysis

available (n=6 studies), comprehensive pulmonary rehabilitation programs that
incorporated exercise, education and social support reported significantly reduced
anxiety and depression in people with COPD compared to standard care (98).
However, there was large heterogeneity in the pulmonary rehabilitation programs,
making it difficult to determine which aspects of the pulmonary rehabilitation program
had the greatest impact on psychological symptomatology (98).

26

2.7.3 Self-management programs
Self-management programs in people with COPD are defined as “structured but
personalised and often multi-component, with goals of motivating, engaging and
supporting the patients to positively adapt their health behaviour(s) and develop
better skills to manage their disease” (p4) (99). Self-management programs have
historically been developed for a variety of medical populations, employed in a variety
of settings (e.g. clinical and primary care settings) using an array of mediums (e.g.
video-based programs, Internet-based programs) and may or may not include support
from a healthcare provider/team. To date, there are limited data available on the
efficacy of self-management programs to treat anxiety and depression in people with
COPD, as most self-management programs mainly focus on physiological outcomes
and health-care use (100). However, results from a recent Cochrane review (n=29
included studies) found self-management improved HRQoL in people with COPD
compared to usual care, providing support for the use of this treatment to alleviate
mental health disorders in this population (101). Growing support is also provided by
two recent studies which specifically examined the benefits of a self-management
program designed to treat anxiety and depression in people with COPD. The first, by
Howard and Dupont (n=222) investigated a self-management ‘COPD breathlessness
manual’ based on the principles of cognitive behavioural therapy, relative to usual
care. Results indicated those who participated in the five week home-based selfmanagement intervention significantly decreased their anxiety and depression
symptomatology at six months compared to usual care (38). The second, a study by
Jiang and He (n=96) investigated an uncertainty management intervention in the form
of an audio CD and self-help manual, complimented by telephone guidance provided
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by a nurse against usual care. They found a significant reduction in anxiety and
depression at 10 month follow-up in the intervention group compared to usual care
(35). These promising studies highlight the need for continued research into the
efficacy of self-management programs on psychological symptomatology in people
with COPD.

2.7.4 Self-help groups
Self-help groups are typically small voluntary groups, structured for the mutual help of
its members and are widely used by people with a chronic disease. Face-to-face social
interaction in these groups is highly encouraged to facilitate the feeling of a helpful
support network (94). The numerous benefits of self-help groups include enhanced
perceived social support and associated psychological benefits which may stem from a
general increase of positive emotions, a boost in self-esteem and feelings of control
and stability of one’s environment (102, 103). Whilst self-help group sessions are often
incorporated in pulmonary rehabilitation programs or self-management programs,
there is a paucity of data on the effectiveness of the use of these groups in the
literature. To date, there are no studies reporting the efficacy of an intervention that
only consists of a self-help support group to treat anxiety and depression in people
with COPD.
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2.7.5 Psychotherapy

2.7.5.1 Relaxation therapy
The aim of relaxation therapy is to facilitate the relaxation response by effectively
dealing with some of the physiological responses which may accompany feelings of
anxiety, as well as increasing a person’s perception of self-control, and thus ultimately
wellbeing (86). Regulation of the sympathetic nervous system and stimulation of
certain regions of the hypothalamus which control the ‘flight or fight’ response is
central to this relaxation response (104). Relaxation therapy encompasses an
assortment of techniques including: breathing exercises, progressive muscle
relaxation, isometric muscle relaxation, biofeedback, meditation and hypnosis. (94).
Relaxation therapy has been found to be effective in reducing a range of symptoms
(e.g. hypertension, pain and insomnia) in other chronic diseases such as cardiovascular
disease and cancer (105). However, despite relaxation therapy often forming a
component of pulmonary rehabilitation, cognitive behavioural therapy and selfmanagement programs in people with COPD, there is limited literature about the
immediate and long-term effects of these techniques on reducing anxiety and
depression in people with COPD. A recent meta-analysis of relaxation therapy in a
COPD population conducted by Volpato et al. (2015) found a slight effect on improving
psychological wellbeing but acknowledged “higher quality research is required” (p1)
(106).
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2.7.5.2 Cognitive Behavioural Therapy (CBT)
CBT is a structured, psychological intervention whereby the participant works
collaboratively with the therapist to identify the types and effects of thoughts, beliefs
and interpretations of current symptoms, feeling states and/or problem areas (40).
CBT combines both cognitive interventions (cognitive restructuring i.e. attempts to
alter individual appraisals and thinking patterns) and behavioural interventions to
reduce dysfunctional emotions and behaviours. Such therapies are used to change the
way people think and act and to give them a sense of control and encourage
engagement in coping (40). The use of CBT is effective in treating many mental health
problems, and international guidelines recommend CBT as the treatment of choice for
a range of anxiety and mood disorders in the general healthy population. CBT
treatment of these psychological disorders assists participants to recognise and
challenge the negative thinking patterns and irrational beliefs that typically fuel their
psychological symptomatology. CBT generally runs over 12 weeks and can be
conducted either individually or in groups of people who are experiencing the same
problems (107).

CBT has shown potential as a treatment to improve anxiety and depression in a variety
of chronic illnesses including cancer (particularly lung and breast), diabetes mellitus
and Parkinson’s disease (107-112). There is also promising evidence from a growing
body of studies that suggests CBT can also help reduce symptoms of anxiety and
depression in people with COPD. In a recent Cochrane review of psychological
therapies for the treatment of anxiety disorders in people with COPD, the authors
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reported there was some evidence CBT was effective in reducing anxiety
symptomatology (113). However the substantial heterogeneity between the studies
included in the analysis limited the ability to draw reliable conclusions. Support for the
ability of CBT to reduce depression in COPD populations comes from another metaanalysis which reported a small but significant improvement in depression but not
anxiety for this type of intervention (114). Appendix 2.1 presents a summary of 18
published studies that have examined the effect of CBT on COPD populations. The CBT
sessions were highly variable, with some being conducted individually either by faceto-face interview or by telephone, while others were conducted in a group, some as
part of a comprehensive program and others conducted utilising the principles of selfmanagement. Duration of treatment varied from one CBT session to 16, and the
majority of these studies utilised the HADS, BAI and/or BDI-II to screen for anxiety and
depression in their COPD population. The majority of studies found a CBT intervention
significantly reduced symptomatology for anxiety and/or depression relative to the
control group, whether that was treatment as usual, enhanced standard care,
education interventions and/or exercise. In one study by Kunik et al. (2001), as little as
a single intensive two hour session of group CBT was associated with a reduction in
anxiety and depression symptomatology relative to an education-only intervention,
suggesting minimal exposure to CBT is enough to elicit at least some improvement in
psychological outcomes (26). CBT has also been demonstrated to maintain
improvements long-term, with another study by Kunik et al. (2008) reporting a
significant reduction in anxiety and depression at 12 months post-intervention (28),
and a study by Livermore et al. (2010) reporting a significant reduction in anxiety at 18
months post-intervention (33). However, the COPD participants recruited for the
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studies conducted by Kunik et al. were predominately male and from a veterans
hospital, thus limiting the generalisability of these results (26, 28). Broad applicability
of such studies to COPD populations is also difficult due to differences in population
groups between each study, including differences in the proportion of males to
females, the mean age, COPD severity of participants and where they were sourced
(e.g. primary vs secondary care patients). Of the three studies that found CBT had no
effect on anxiety and depression, two studies had extremely small sample sizes (n=8
and n=18) and therefore underpowered to detect a statistically significant difference,
the CBT treatment was quite demanding for all three studies (8 x 90 minute sessions, 6
x 90 minute sessions and 10 x 60 minute sessions) and there was a very short followup period (nil, 12 weeks and nil) (25, 44, 47). These reasons may partly explain why no
effect was found.

To date, there have been two studies conducted in Australia exploring the
effectiveness of CBT in people with COPD. The first, by Livermore et al. (2010)
recruited people with COPD who had undergone pulmonary rehabilitation (n=41) and
randomised them into a CBT intervention whereby participants were individually
administered weekly hour long sessions over four weeks (n=21) or a routine care group
(n=20). Assessments were made at baseline, post-intervention and at six, 12 and 18
month intervals. The study found significant reductions in anxiety and catastrophic
cognitions in the CBT group at follow-up compared to usual care. Livermore also found
the CBT group did not experience any panic attacks during follow-up whereas patients
in the routine care group did (60%) (33). The second study by Walters et al. (2013)
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recruited people with COPD from general practises (n=182) and investigated CBT in a
self-management format where it was delivered via nurses over the telephone.
Participants were randomised into a ‘telephone health monitoring’ group where they
received CBT via 16 x 30 minute phone calls over a year or in to a control group which
received usual care as provided by a GP and a regular monthly phone call. Assessments
were made at baseline, 6 months and post-intervention. Those in the telephone health
monitoring group had significantly reduced anxiety but not depression (36).

Despite the promising efficacy of CBT in people with COPD, a common problem
encountered by investigational studies are the relatively high attrition rates of up to
27–47% reported (28, 32, 44). This is a problem as it may demonstrate the
impracticality of conducting CBT sessions in COPD populations. Whilst not every study
reported reasons for the attrition from CBT programs, of the few that did, competing
illness and logistical problems with time and transportation were barriers reported (25,
27, 28, 31, 44). There is a clear need to investigate the facilitators and barriers to
people with COPD attending CBT in order to address these issues to develop a feasible
treatment for this population. Furthermore, research into the benefits of selfmanagement CBT is warranted due to the limited literature currently available of its
effectiveness.

2.8

Theoretical Framework

The cognitive behavioural model was adopted for this thesis. The cognitive behavioural
model of panic has emerged as a widely accepted theory for onset of anxiety in people
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with COPD. As the fundamental basis for this model stems from the idea that
catastrophic cognitions (thoughts) are the cause of anxiety, and that these cognitions
are misinterpretations which can be reversed, this model provides a compelling
rationale for the use of CBT to treat this comorbidity. CBT is based upon the theory
that thoughts affect feelings, which in turn has a flow-on effect on behaviours, which
then consequently affects thoughts again in a constant cycle (Figure 2.1).

Behaviours

Thoughts

Feelings

Figure 2.1 Cognitive behavioural theory

The cognitive behavioural theory suggests when CBT is applied in people with COPD,
the negative feedback loop (Figure 2.2) of the dyspnoea-anxiety-dyspnoea cycle
experienced by people with COPD, is interrupted.
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Reduced
activity and
fatigue

Induced
shortness of
breath

Increased
shortness of
breath and
anxiety

Anxiety,
panic attacks

Figure 2.2 The dyspnoea-anxiety-dyspnoea cycle

CBT also has the potential to alleviate symptoms of depression commonly experienced
by people living with COPD by restructuring pessimistic thought patterns and negative
behaviours. The use of CBT in people with COPD aims to help participants recognise
their dysfunctional thinking patterns and factors contributing to their anxiety and
depression, and re-interpret their physiological and cognitive symptoms in a more
positive manner.

2.9

Summary

Anxiety and depression are common comorbidities in people with COPD which
contribute to greater morbidity and mortality. The cognitive behavioural model has
emerged as a widely accepted theory for onset of psychological symptomatology in
this population, and there is promising evidence to suggest CBT improves mental
health outcomes by disrupting this cycle. However, there is a need for an alternative
modality of CBT delivery for people with COPD suffering from anxiety and depression
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to overcome the logistical barriers reported by previous investigational studies. Thus, a
novel home-based self-management CBT learning resource in a DVD format was
developed with an accompanying manual. The primary aim of this thesis was to
investigate the efficacy of CBT delivered as traditional group therapy with a reduced
number of sessions, and this novel home-based self-management DVD resource
compared to usual care, to improve anxiety and depression symptomatology. The
secondary aim was to investigate the efficacy of these interventions on improvement
in HRQoL. This thesis also sought to investigate the risk factors associated with
psychological symptomatology, the most suitable tool(s) for screening anxiety and
depression and to explore participants’ experiences of CBT to understand the enablers
and disablers for people with COPD to successfully enrol and complete a course.
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2.10 Appendix
Appendix 2.1 Cognitive behavioural therapy in people with COPD
Population
and country

Design

Sample

Treatment

Delivery of
CBT

Psychological
outcome
measures

Time-points

Attrition
rate

Outcome*

Lisansky &
Clough 1996
(44)

Self-selected
convenience
sample, USA

Onegroup
pre- and
post-test

n=8; mean age=70 (SD
not specified);
m=38%; f=63%

1. CBT: 8 x 90 minute
weekly sessions, (one
group of 8) (n=8)

Researchers
and nurse

Kellner’s
Symptom
Questionnaire
(SQ)

Pre- and postintervention

31%

No change in symptoms
of anxiety disorders or
depression posttreatment

Eiser et al.
1997 (47)

Outpatients,
England

Repeated
measures
pre-post

n=18; intervention
group: mean age=73
(SD not specified),
m=40%, f=60%;
control group: mean
age=71, m=50%; f=
50%

1. CBT: 6 x 90 minute
weekly sessions (groups
of 5–6) (n=10)
2. Control: 6 x 6 minute
walking tests & lung
function tests per week,
no psychotherapy
(groups of 5–6) (n=8)

Psychiatrist

HADS

1. CBT: Preintervention,
post
intervention
and follow-up
at 12 weeks
2. Control:
Baseline, week
2 and week 7

10%

No change in symptoms
of anxiety or depression
post-treatment

Emery et al.
1998 (25)

Community
participants via
advertising and
physician
referral, USA

RCT

n=79;
mean age=67±6.5;
m=47%; f=53%

1. Exercise, education
and stress management:
10 weeks of exercise, 16
education and 10 x 1
hour stress management
sessions based on CBT
(n=29)
2. Education and stress
management: 16
education and 10 x 1
hour stress management
sessions based on CBT
(n=25)
3. Control: Waiting List
(n=25)

Clinical
psychologist

CES-D, The
BradburnAffect-Balance
Scale, STAI, SCL90-R

Pre- and postintervention

11%

Exercise, education and
stress management
group significantly
decreased symptoms of
anxiety and depression .
Waiting List group also
significantly decreased
symptoms of
depression.
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Author

Population
and country

Design

Sample

Treatment

Delivery of
CBT

Psychological
outcome
measures

Time-points

Attrition
rate

Outcome*

Kunik et al.
2001 (26)

Patients from a
veteran hospital
& advertising,
USA

Single
blind RCT

n=53;
mean age =71±5.9;
m=83%; f=17%

Gero psychiatrist and
internist

BAI, GDS,
SF-36

Pre- and postintervention

9%

CBT significantly
decreased symptoms of
anxiety and depression

de Godoy &
de Godoy
2003 (27)

Outpatients
attending PR,
Brazil

Single
blind RCT

n=30; intervention
group: mean age=
62±14.9; m=86%,
f=14%; control group:
mean age=59±11.8,
m=63%, f=37%

1. CBT: 1 x 2 hour group
session (6–10
participants) and weekly
phone calls for 6 weeks
(n=21)
2. Control: 1 x 2 hour
education session
(groups of 6–10) and
weekly phone call for 6
weeks (n=27)
1. PR: 12 week program,
each week: 2 x
physiotherapy sessions,
2 x physical exercise
sessions, 1 x CBT session
(groups or individual not
specified) and 1 x
educational session
p/month (n=14)
2. Control: same as PR
group with no CBT
(n=16)

Not specified

BAI, BDI

Pre- and postintervention

Not
reported

PR group with CBT
significantly reduced
symptoms of anxiety
and depression

de Godoy et
al. 2005 (48)

Outpatients,
Brazil

Single
blind RCT

n=49,
mean age not
specified (all >50
years), m=73%, f=27%

12 week PR program:
G1: 2 x weekly physical
exercise sessions,
weekly individual
psychotherapy sessions,
monthly group
education sessions, 2 x
weekly physical therapy
(n=19)
G2: Same as G1without
physical therapy (n=16)
G3: Same as G1 without
individual
psychotherapy (n=14)

Psychologist

BAI, BDI

Pre- and postintervention

Not
reported

Groups 1 and 2
significantly reduced
symptoms of anxiety
and depression. Group 3
significantly reduced
symptoms of anxiety but
not depression
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Author

Population
and country

Design

Sample

Treatment

Delivery of
CBT

Psychological
outcome
measures

Time-points

Attrition
rate

Outcome*

Kunik et al.
2008 (28)

Patients from a
veteran hospital
& advertising,
USA

Single
blind RCT

n=238; intervention
group:
mean age=66±10.1,
m=97%, f=3%; control
group: mean
age=67±10.4, m=96%,
f=4%

1. CBT: 8 x weekly 1
hour group sessions (up
to 10 participants)
(n=118)
2. Control: 8 x 1 hour
sessions of COPD
education (n=120)

Psychology
interns and
post-doctoral
fellow

SF-36, BAI, BDIII

Preintervention, 4
weeks, postintervention
and follow-up
at 4, 8 and 12
months

27%

Both groups significantly
reduced symptoms of
anxiety disorders and
depression posttreatment.
Improvements were
maintained with no
significant change during
follow-up

Heslop et al.
2009 (29)

Outpatients,
England

Repeated
measures
pre-post

n=10; mean age=68
(SD not specified);
m=50%; f=50%

1. CBT: Individual
fortnightly sessions
(length not specified),
(average 4 sessions,
range 2–13 sessions)
(n=10)

Respiratory
nurse

HADS

Preintervention
and postintervention
(varying 2-4
weeks after
intervention)

Nil

Significantly reduced
symptoms of anxiety
and depression

Howard et al.
2010 (30)

Outpatients,
England

Repeated
measures
pre-post

n=48; intervention
group: mean
age=70.9±9.6, m=60%,
f=40%; control group:
mean age=72.9±10.0,
m=60%, f=40%

1. Cognitive-behavioural
breathlessness
intervention: 4 x weekly
2 hour sessions (groups
of up to 10)

Team consisting
of a
psychologist,
respiratory
clinical nurse
specialist,
health
psychologist,
physio-therapist
and
occupational
therapist

HADS

Pre- and postintervention
and follow-up
at 6 weeks

Not
specified

Significantly reduced
symptoms of depression
but not anxiety at postintervention and followup
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Author

Population
and country

Design

Sample

Treatment

Delivery of
CBT

Psychological
outcome
measures

Time-points

Attrition
rate

Outcome*

Hynninen et
al. 2010 (31)

Outpatient
pulmonary
clinic and
newspaper
advertising,
Norway

RCT using
matched
pairs

N=51; intervention
group mean
age=59±7.6; control
group mean age=
63±9.9; total m=50%,
f=50%

Post-graduate
psychology
student

BAI, BDI-II

Pre-and postintervention
and follow-up
at 6 months

17%

CBT significantly
reduced symptoms of
anxiety and depression
post-treatment
compared to control
group. Decrease in
anxiety (but not
depression) also
maintained at follow-up
for CBT group compared
to control group

Lamers et al.
2010 (32)

Patients from
general
practises,
Netherlands

RCT

n=187; intervention
group: mean
age=71±6.3; m=62%,
f=38%; control group:
mean age=72±7.1,
m=58%, f=42%

1. CBT: 7 x weekly 2
hour group sessions (4–6
participants) and phone
call at 1 and 3 months
post-treatment (n=25)
2. Control: enhanced
standard care for COPD
(groups of 4–6) and
phone call every two
weeks during
intervention period to
monitor psychological
status (n=26)
1. Minimal Psychological
Intervention with
elements of CBT and
self-management: 2–10
visits depending on
patient progress over a
period of at most 3
months (n=96)
2. Control group: Care as
usual (n=91)

Nurse

SCL-90-R, BDI

Pre- and postintervention (1
week) and
follow-up at 3
and 9 months

47%

Minimal Psychological
Intervention group
significantly reduced
symptoms of anxiety
and depression at 9
months compared to
usual care

Livermore et
al. 2010 (33)

Hospital
outpatients and
in-patients,
Australia

RCT

n=41; intervention
group mean
age=73±6.4; control
group mean age=
74±8.1; total m=24%;
f=76%

1. CBT: 4 x 1 hour
weekly individual
sessions (n=21)
2. Control: routine care
(n=20)

Researcher

ADIS-IV, HADS

Pre- and postintervention
and follow- up
at 6, 12 and 18
months

15%

Significantly reduced
symptoms of anxiety
and no experiences of
panic attacks in CBT
group compared to
control at posttreatment and follow
up.
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Author

Population
and country

Design

Sample

Treatment

Delivery of
CBT

Psychological
outcome
measures

Time-points

Attrition
rate

Outcome*

Kapella et al.
2011 (34)

Community
participants via
advertising,
USA

Mixed
method

n=23; phase 1 group:
mean age=60±10.0,
m=78%, f=22%; phase
2 group: mean
age=65±9.0; m=78%,
f=22%

1. Phase 1: 6 x 1 hour
weekly CBT sessions
(n=5)
2. Phase 2:
CBT: 6 x 1 hour weekly
sessions (n=9) or 6 x
wellness education
sessions (9)

Specialised
nurse

POMS

Pre- and postintervention

One person
dropped
out

Wellness education
sessions significantly
reduced symptoms of
depression but not
anxiety post- treatment
compared to CBT

Jiang and He
2012 (35)

Outpatients,
China

RCT

n=96; intervention
group: mean
age=65±9.0, m=71%,
f=29%; control group:
mean age:65±8.1,
m=68%, f=32%

1. Uncertainty
Management: 4 x 35
minute telephone calls
weekly based on CBT,
last 2 calls used to guide
participants through
audio CD and self-help
manual (n=50)
2. Control group:
standard care (n=50)

Research nurse

STAI, HADS
Depression
Subscale

Preintervention
and 10 month
follow-up

3%

Uncertainty
Management
significantly reduced
symptoms of anxiety
and depression

Walters et al.
2013 (36)

Patients from
general
practises,
Australia

Cluster
RCT

n=182; intervention
group: mean
age=68.2±7.9; m=54%,
f=46%; control group:
mean age= 67.3±7.6,
m=51%, f=49%

1. Telephone Cognitive
Behavioural Health
Monitoring: 16 x 30
minute phone calls over
12 months (n=90)
2. Control group: Usual
care as provided by a GP
plus regular monthly
phone call from research
nurse (n=92)

Community
health nurses

HADS, CES-D,
Post-Traumatic
Stress Disorder
ChecklistCivilian Version,
SF-36

Preintervention, 6
months and
postintervention

18%

Telephone Health
Monitoring significantly
reduced symptoms of
anxiety but not
depression
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Author

Population
and country

Design

Sample

Treatment

Delivery of
CBT

Psychological
outcome
measures

Time-points

Attrition
rate

Outcome*

Blumenthal
et al. 2014
(37)

Outpatients
recruited from
university
hospitals, USA

RCT

n=326; intervention
group: mean
age=66±7.9, m=62%,
f=38%; control group:
mean age=66±8.7,
m=60%, f=40%

1. Telehealth Cognitive
Behavioural Coping Skills
Training: 12 x weekly
telephone sessions
followed by 2 x biweekly sessions for 1
month (total 14 sessions
roughly 30 minutes in
duration over 16 weeks)
(n=162)
2. Control Group: COPD
education. Same as
above (n=164)

Clinical
psychologists
and health
educators

STAI, BDI-II, SF36?

Pre-and postintervention

7%

Telehealth Coping Skills
Training significantly
reduced symptoms of
anxiety and depression
compared to COPD
education

Howard &
Dupont,
2014 (38)

Patients from
GP practises,
England

Single
blind RCT

n=222; intervention
group: mean
age=71±10.4, m=56%,
f=44%; control group:
mean age=73±11.4,
m=41%, f=59%

Psychologists

HADS

Pre- and postintervention,
and follow-up
at 6 months

2%

Cognitive Behavioural
Manual significantly
reduced symptoms of
anxiety and depression
at 6 months follow-up

Bove et al.,
2016 (43)

Outpatients,
Denmark

RCT

n=66; intervention
group: mean
age=71±8.39; m=33%,
f=67%; control group:
mean age=70±8.73,
m=33%, f=67%

1. Cognitive Behavioural
Manual (n=112)
2. Control: British Lung
Foundation Information
Booklets (n=110)
Both groups encouraged
to follow their program
for 1 hour per day over 5
weeks.
2 x telephone booster
call sessions provided at
weeks 3 and 6.
1. 1 x home-based CBT
and psychoeducation
session (mean duration
of 1 hour) and 1 x 20
minute telephone
booster session 2 weeks
after
2. Control: standard care
(n=33)

Nurse

HADS

Pre- and postintervention
and follow-up
at 1 and 3
months

10%

Home-based CBT and
pschoeducation
significantly reduced
Symptoms of anxiety at
post-treatment and
follow-up

42

Author

BAI: Beck Anxiety Inventory; BDI: Beck Depression Inventory; CES-D: The Centre for Epidemiological Studies—Depression Inventory; GDS: Geriatric Depression Scale; HADS: Hospital Anxiety and
Depression Scale; POMS: Profile of Mood States PR: Pulmonary Rehabilitation; SCL-90-R: The Hopkins Symptom Checklist; STAI: The State-Trait Anxiety Inventory; RCT: Randomised Control Trial
*Effect sizes not summarised due to unreported data and inconsistent coefficients used within the literature

CHAPTER THREE

Determinants of concomitant anxiety and depression in people with chronic
obstructive pulmonary disease

This manuscript was submitted for publication in the Journal of Psychosomatic
Research on the 2nd of October 2017 and is currently under review.

Tina Phan, Owen Carter, Grant Waterer, Li Ping Chung, Maxine Hawkins, Cobie Rudd,
Mel Ziman & Natalie Strobel. Determinants of concomitant anxiety and depression in
people with chronic obstructive pulmonary disease. Journal of Psychosomatic
Research. (Submitted for review on 2 October 2017).
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3 Study rationale

People with chronic obstructive pulmonary disease (COPD) frequently suffer from both
anxiety and depression. However, the literature surrounding determinants for having
both these psychological comorbidities is limited. Furthermore, generalisability of
results are constrained due to the populations sampled. The following chapter (Study
One) seeks to investigate the determinants of concomitant anxiety and depression in a
more representative sample of people with COPD than previously used. It was
hypothesised previous risk factors identified separately for anxiety or depression in
people with COPD were also shared risk factors for concomitant anxiety and
depression.

This study was cross-sectional in design, and utilised baseline data collected from the
Breathing New Life study to provide a picture of prevalence in an Australian COPD
population. In addition, we also assessed the association between demographic
predictor variables and psychological symptomatology score using logistic regression.
Three factors were found to increase the risk of having both anxiety and depression in
our COPD cohort: younger age, previous history of psychological illness and greater
number of non-psychological comorbidities.
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CHAPTER FOUR

Discriminant validity of the Hospital Anxiety and Depression Scale, Beck Depression
Inventory (II) and Beck Anxiety Inventory to confirmed clinical diagnosis of
depression and anxiety in patients with chronic obstructive pulmonary disease

This manuscript was submitted for publication in the journal Chronic Respiratory
Disease on the 6th of May 2015, was invited for second review on the 11th of November
2015 and resubmitted on the 1st of December 2015. It was accepted for publication on
the 17th of December 2015 and available online ahead of print on the 3rd of March
2016.

Tina Phan, Owen Carter, Claire Adams, Grant Waterer, Li Ping Chung, Maxine Hawkins,
Cobie Rudd, Mel Ziman & Natalie Strobel. Discriminant validity of the Hospital Anxiety
and Depression Scale, Beck Depression Inventory (II) and Beck Anxiety Inventory to
confirmed clinical diagnosis of depression and anxiety in patients with chronic
obstructive pulmonary disease. Chron Respir Dis. 2016;13(3):220-228.
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4 Study rationale

There is a lack of recommendations for psychological comorbidity screening measures
in the Global Initiative for Chronic Obstructive Lung Disease management guidelines,
and despite being commonly used in people with chronic obstructive pulmonary
disease (COPD), the Hospital Anxiety and Depression Scale (HADS) has only been
validated for use in this population twice beforehand and not at all for the Beck
Depression Inventory (BDI-II) and Beck Anxiety Inventory (BAI). The following chapter
(Study Two) seeks to add to the limited body of literature by investigating the
discriminant validity of the HADS with people diagnosed with COPD, and to examine
the discriminant validity of the BDI-II and BAI as potential alternatives for this
population. It was hypothesised the BDI-II and BAI may be better alternatives to
screening people with COPD for psychological symptomology than the HADS.

This study used a subset of people from the wider Breathing New Life study cohort
who were randomised to additionally self-complete the HADS, followed by a
structured clinical interview with a provisional psychologist conducting the Mini
Neuropsychiatric Interview (MINI) at baseline. Results of this study did not replicate
previously reported low sensitivity and specificity of the HADS depression subscale
(HADS-D) in people with COPD. However, the HADS anxiety subscale (HADS-A) as well
as

the

BDI-II

and

BAI

produced

acceptable

sensitivity

and

specificity.

Recommendations for simple modifications of the HADS-D to improve its sensitivity
and specificity for depression are given.
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4.1

Abstract

Objectives
To investigate the discriminant validity of commonly used depression and
anxiety screening tools in order to determine the most suitable for patients with
chronic obstructive pulmonary disease (COPD).

Methods
COPD patients (n=56) completed the Hospital Anxiety and Depression Scale (HADS),
Beck Depression Inventory (BDI-II) and Beck Anxiety Inventory (BAI). These scores were
compared to confirmed clinical diagnoses of depression and anxiety using the Mini
Neuropsychiatric Interview (MINI).

Results
HADS-D sensitivity/specificity was 78/81%; BDI-II 89/77%; HADS-A 71/81%; and BAI
89/62%. HADS-D sensitivity/specificity was improved (100/83%) with removal of Q4 ‘I
feel as if I am slowed down’ and adjusted cut-off (≥5). Removal of BDI-II Q21 ‘Loss of
interest in sex’ with adjusted cut-off ≥12 resulted in similar improvement (100/79%).
No problematic items were identified for HADS-A or BAI.
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Conclusions
Previously reported low sensitivity/specificity of the HADS for COPD patients was not
replicated. Furthermore, simple modifications of the HADS-D markedly improved
sensitivity/specificity for depression. BDI-II, HADS-A and BAI produced acceptable
sensitivity/specificity unmodified. Pending further research, for COPD patients we
recommend continued use of the HADS-A with standard cut-off (≥8) and removal of Q4
of the HADS-D with lower cut-off ≥5.

4.2

Introduction

Depression and anxiety are common comorbidities in patients diagnosed with chronic
obstructive pulmonary disease (COPD), with benchmark prevalence estimates of 40%
for depression and 36% for anxiety (10). Screening COPD patients for concomitant
psychological distress is important as it has been found to contribute to poorer health
outcomes across a number of domains, including: increased exacerbation rates,
diminished exercise performance and functional mobility, reduced health-related
quality of life, increased number of emergency hospital visits, increased
hospitalisations, increased length of stay as an admitted patient, increased mortality
rates and in general greater economic burden (14-17, 19, 20, 22). Consequently,
European and Australasian COPD management guidelines recommend routine
screening for depression and anxiety in COPD patients using the Hospital Anxiety and
Depression Scale (HADS) (115, 116). Use of the HADS with COPD patients is
widespread; being reported in at least 17 published studies (11, 16, 19, 41, 45, 47, 56,
65-74). However, only two previous studies have investigated the discriminant validity
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of the HADS with COPD populations and both cast doubt about its usefulness. Cheung
et al. confirmed clinical diagnoses of anxiety disorders with 55 elderly New Zealand
COPD patients using the Mini Neuropsychiatric Interview (MINI) and reported at the
standard

cut-off

≥8

the

HADS

anxiety

subscale

(HADS-A)

provided

sensitivity/specificity of 36/90% and Area Under Curve (AUC) of 79% (45). They
recommended a lower cut-off ≥4 that yielded an improved sensitivity/specificity of
79/71%. Nowak et al. used the German version of the HADS depression subscale
(HADS-D) to assess 259 Swiss COPD patients for depression, cross-referenced with
diagnoses of depression co-morbidity noted in patients’ clinical records, and also
reported low discriminant validity at the standard cut-off ≥8 (sensitivity/specificity
25/84%; AUC 66%) (46). They recommended a lower optimal cut-off score of ≥5 but
this still yielded fairly low sensitivity/specificity 62/63%. These results cast doubt over
the appropriateness of using the HADS for patients with COPD. However, these results
demand replication before any firm conclusions can be drawn.

Potential alternatives to the HADS for COPD patients include the Beck Depression
Inventory (II), also a popular research measure to screen COPD patients for depression,
and the counterpart for anxiety, the Beck Anxiety Inventory (BAI). These tests are
longer than the HADS, with 21 items each, compared to the 14 items in total for the
HADS, but are well established and popular for screening COPD patients for studies
involving cognitive behavioural therapy (26-28, 31). However, we are unaware of any
studies that have established the discriminant validity of either the BDI-II or BAI in
COPD patients. Therefore, the aims of the present study were to investigate the
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discriminant validity of the HADS with patients diagnosed with COPD, and to examine
the discriminant validity of the BDI-II and BAI as potential alternatives for this
population.

4.3

Method

4.3.1 Sample
Participants were outpatients attending community-based COPD clinics in Perth,
Western Australia. Participants were excluded if they had a life expectancy of less than
six months, were currently involved in another research study, had an illness
exacerbation resulting in hospitalisation within the previous month, were not fluent in
English, or were blind, deaf or diagnosed with dementia or Alzheimer’s disease. Ethics
approval for the study was granted by Royal Perth Hospital, Edith Cowan University
and the South Metropolitan Health Service Human Research ethics committees. We
attempted to contact a list of 164 outpatients. Thirty-five individuals were uncontactable because they were either deceased, discharged from the clinics, had
disconnected telephones or we were unable to contact them after five separate
attempts. Of the 129 successfully contacted, 27 did not meet our inclusion criteria and
46 declined to participate, citing ill-health or ‘lack of time’. The final sample consisted
of 56 patients with confirmed diagnosis of COPD by respiratory physicians who gave
their informed consent to participate in the study, representing 34% of our original
sampling pool, and a consent rate of 55% of contactable and eligible participants. The
mean age of participants was 73.3 years (SD 8.9; range 50–91). There were more
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females (58.9%) than males (41.1%) and the majority of participants were retired
(73.2%) and married or in a de-facto relationship (69.7%) (Table 4.1).

Table 4.1 Participant characteristics
Characteristic
Males
Female
Aboriginal or Torres Strait Islander
Education
Up to 10 years of school
11 years and above
Other
Marital status
Married/De-facto
Not in a current relationship
Has a carer
Occupation
Employed
Retired
Other
GOLD stage
Mild
Moderate
Severe
Very severe
Missing

N
23
33
1

%
41.1
58.9
1.8

26
27
3

46.4
48.2
5.4

39
17
41

69.7
30.3
73.2

4
41
11

7.2
73.2
19.6

2
18
25
3
8

3.6
32.1
44.6
5.4
14.3

4.3.2 Instruments
Participants were asked to self-complete the HADS, BDI-II and BAI, followed
immediately by a structured clinical interview with a provisional psychologist
conducting the MINI. The MINI (v6.0.0) is considered a ‘gold standard’ in determining
incidence of Axis I psychiatric disorders as per DSM-IV and ICD-10 criteria (117). The
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provisional psychologist was blinded to the results of the other questionnaires before
conducting the MINI.

4.4

Statistical analyses

Aggregated and item-by-item scores were examined for the HADS, BDI-II and BAI and
compared to clinically-confirmed current major depression and any anxiety disorders
(panic disorder, agoraphobia and generalised anxiety disorder) based upon MINI
diagnostic criteria. The sensitivity, specificity, Youden’s index J, positive predictive
value, negative predictive value, kappa coefficient and AUC values were calculated
using the MINI as the clinical standard for the presence or absence of psychological
comorbidity. Independent samples t-tests were also used to compare the mean HADS,
BDI-II and BAI scores of participants in various groups. IBM SPSS (v22) was used for all
statistical analyses.

4.5

Results

4.5.1 Depression
Nine of 56 patients (16.1%) met the clinical diagnosis for major depression according
to the MINI. The mean HADS-D and BDI-II scores for these patients are compared to
others in Table 4.2.
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Table 4.2 Proportions and averages of depression and anxiety scores for the MINI,
HADS-D, HADS-A, BDI and BAI
Depression Measure
Prevalence
Average scores with
depression
Average scores without
depression

Anxiety Measure
Prevalence
Average scores with
anxiety
Average scores without
anxiety

MINI

HADS-D ≥8

BDI-II ≥14

16% (95% CI ±10)

29% (95% CI: 11.8)

34% (95% CI: ±12.4)

-

12.33 (SD = 4.15)

32.44 (SD = 12.04)

-

4.34 (SD = 2.83)*

9.40 (SD = 8.21)*

MINI

HADS-A ≥8

BAI ≥8

25% (95% CI 14–36%)

32% (95% CI: ±12.2)

48% (95% CI: ±13.1)

-

9.14 (SD = 4.07)

20.79 (SD = 12.63)

-

4.36 (SD = 4.03)*

8.60 (SD = 10.39)*

*denotes statistically significant difference to participants with depression at p<0.001

Both HADS-D and BDI-II scores were significantly different between participants with
clinically confirmed depression compared to those without. AUC statistics for the
HADS-D and BDI-II were both close to perfect (94.8%, p<0.001; 94.9%, p<0.001
respectively). As can be seen in Table 4.3, the recommended HADS-D cut-off of ≥8
identified 7 out of 9 (77.8%) true positive cases and 38 out of 47 (80.9%) true negative
cases. Youden’s index J suggested a similar optimal cut-off of ≥7. The mean score of
false positive cases was significantly lower (M = 9.38, SD = 1.30) than true positives (M
= 13.86, SD = 3.29) (t(8.36)=-3.571, p=0.003). The recommended BDI-II cut-off ≥14
identified 8 out of 9 (88.9%) true positive cases and 36 of 47 (76.6%) true negative
cases. Youden’s index J suggested a similar optimal cut-off of ≥13. BDI-II true positives
cases had a significantly higher mean score (M = 32.4, SD = 12.0) than the false
negative cases (M = 22.5, SD = 5.6) (t(18)=-2.454, p=0.025).
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An examination of each item of the HADS-D using independent samples t-tests
identified the mean score for Question 4 ‘I feel as if I am slowed down’ as substanitally
higher than all other items. This was the only item of the HADS-D for which no
participant scored zero, and the only item for which there was no statistically
significant difference in mean scores between those with clinically diagnosed
depression (M = 2.56, SD = 0.73) and those without (M = 2.09, SD = 0.86) (t(54)=-1.544,
p=0.128). The sensitivity and specificity of the HADS-D was therefore recalculated
when excluding this item. With Question 4 excluded, Youden’s index J suggested an
optimal cut-off of ≥5 which detected all true positive cases (100.0%) and 39 out of 47
true negative cases (83.0%) within our sample (Table 4.3). True positive cases still had
a significantly higher mean HADS-D score (M = 11.0, SD = 3.22) than false positive
cases (M = 6.33, SD = 1.80) (t(14)=-3.694, p=0.002).

Independent samples t-tests for each item of the BDI-II also highlighted Question 21.
The mean score for Question 21 ‘Loss of interest in sex’ did not differ significantly
between those with a clinical diagnosis of depression (M = 1.30, SD = 0.43) and those
without (M = 1.32, SD = 1.92) (t(54)= -1.181, p=0.243). Therefore, the sensitivity and
specificity of the BDI-II was recalculated to exclude Question 21. Upon removal of
Question 21, Youden’s index J suggested an optimal cut-off of ≥12 that detected all
true positive cases (100.0%) and 37 out of 47 true negative cases (78.7%) within our
sample (Table 4.3).
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Table 4.3 The sensitivity and specificity of the HADS-D, HADS-D excluding Question 4,
BDI-II and BDI-II excluding Question 21 for detecting major depression in COPD
patients (%)
Cut-off points
HADS-D
3
4
5
6
7**
8
9
10
11
HADS-D ex Qu 4
1
2
3
4
5**
6
7
8
9
BDI-II
9
10
11
12
13**
14
15
16
17
BDI-II ex Qu 21
8
9
10
11
12**
13
14
15
16

Sensitivity

Specificity

Youden’s
index J

PPV*

NPV*

100.0
100.0
100.0
100.0
100.0
77.8
77.8
77.8
55.6

31.9
46.8
57.4
74.5
78.7
80.9
85.1
91.5
95.7

0.32
0.47
0.57
0.75
0.79
0.59
0.63
0.69
0.51

22.0
26.5
31.0
42.9
47.4
43.8
50.0
63.6
71.4

100
100
100
100
100
95.0
95.2
95.5
91.8

100.0
100.0
100.0
100.0
100.0
88.9
77.8
55.6
55.6

28.3
47.8
69.6
78.3
82.6
87.0
93.5
95.7
97.8

0.28
0.48
0.70
0.78
0.83
0.76
0.71
0.51
0.54

21.4
27.3
39.1
47.4
52.9
57.1
70.0
71.4
83.3

100
100
100
100
100
97.6
95.7
91.8
92.0

100.0
100.0
100.0
100.0
100.0
88.9
88.9
88.9
88.9

63.8
70.2
70.2
76.6
76.6
76.6
78.7
78.7
78.7

0.64
0.70
0.70
0.77
0.77
0.66
0.68
0.68
0.68

34.6
39.1
39.1
45.0
45.0
42.1
44.4
44.4
44.4

100
100
100
100
100
97.3
97.4
97.4
97.4

100.0
100.0
100.0
100.0
100.0
88.9
88.9
88.9
88.9

61.7
70.2
74.5
74.5
78.7
78.7
78.7
80.9
80.9

0.62
0.70
0.75
0.75
0.79
0.68
0.68
0.70
0.70

33.3
39.1
42.9
42.9
47.4
44.4
44.4
47.1
47.1

100.0
100.0
100.0
100.0
100.0
97.4
97.4
97.4
97.4

*Note: PPV: positive predictive value, NPV: negative predictive value
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**Optimal cut-off

4.5.2 Anxiety
Fourteen of 56 patients (25.0%) met the MINI criteria for an anxiety disorder. This
included 6 patients diagnosed with panic disorder, 5 with agoraphobia and 3 with
generalised anxiety disorder. Table 4.2 shows the proportion and average scores of
patients identified as meeting the diagnostic criteria for any anxiety disorder via the
MINI and those meeting clinically relevant anxiety symptomatology via the HADS-A
and BAI.

Independent samples t-tests suggested both HADS-A and BAI scores were significantly
different between participants with clinically confirmed anxiety disorders compared to
those without. AUC statistics for the HADS-A and BAI were both in the ‘fair’ range
(78.4%, p<0.01; and 78.5%, p<0.01 respectively). At the recommended cut-off ≥8 the
HADS-A identified 10 out of 14 true positive cases (71.4%) and 34 out of 42 true
negative cases (81.0%). With our sample Youden’s index J suggested an optimal cut-off
of ≥9. There were no significant differences between the mean scores of true positives
(M = 11.20, SD = 2.44) versus false positives (M = 11.38, SD = 2.62) (t(16)=0.146,
p=0.885). With the recommended cut-off ≥8 the BAI identified 11 out of 14 true
positive cases (78.6%) and 26 out of 42 true negative cases (61.9%). For our sample,
the optimal cut-off was ≥12, which maintained true positives at 78.6% but improved
false negatives to 76.2% (Table 4.4). No significant differences in BAI score were found
between true positive cases (M = 25.10, SD = 10.23) and false positive cases either (M
= 18.44, SD = 11.01) (t(16)=-1.542, p=0.136).

56

Table 4.4 The sensitivity and specificity of the HADS-A and BAI for detecting anxiety in
COPD participants
Cut-off points
HADS-A
5
6
7
8
9**
10
11
12
13
BAI
8
9
10
11
12**
13
14
15
16

Sensitivity

Specificity

Youden’s
index J

PPV

NPV

85.7
78.6
71.4
71.4
71.4
64.3
28.6
14.3
14.3

64.3
71.4
78.6
81.0
85.7
85.7
88.1
90.5
92.9

0.50
0.50
0.50
0.52
0.57
0.50
0.17
0.05
0.07

44.4
47.8
52.6
55.6
62.5
60.0
44.4
33.3
40.0

93.1
90.9
89.2
89.5
90.0
87.8
78.7
76.0
76.5

78.6
78.6
78.6
78.6
78.6
71.4
71.4
71.4
71.4

61.9
71.4
76.2
76.2
76.2
78.6
81.0
81.0
81.0

0.41
0.50
0.55
0.55
0.55
0.50
0.52
0.52
0.52

40.7
47.8
52.4
52.4
52.4
52.6
55.6
55.6
55.6

89.7
90.9
91.4
91.4
91.4
89.2
89.5
89.5
89.5

*Note: PPV: positive predictive value, NPV: negative predictive value

**Optimal cut-off

An examination of the mean response to each question within the HADS-A revealed no
conspicuously inflated items for COPD patients.

Examining the mean response to each question within the BAI revealed Question 15
‘Difficulty breathing’ was substantially higher than other items. However, the mean
score for this question remained statistically different between those with clinically
diagnosed anxiety (M = 1.71, SD = 1.07) and those without (M = 1.0, SD = 1.12) (t(54) =
-2.05, p=0.045), suggesting discriminant validity still existed and removal of this item
was therefore not warranted.
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4.6

Discussion

The first aim of this study was to investigate the discriminant validity of the HADS with
patients diagnosed with COPD. We were unable to replicate the findings of Cheung et
al. and Nowak et al. (45, 46). In contrast to Cheung et al., who found a much lower
optimal cut-off for the HADS-A of ≥4, our optimal cut-off (≥9) was a very close
approximation to the standard recommendation of ≥8. The reason for the different
results is far from clear. The proportion of our sample diagnosed with anxiety disorders
(25.0%) corresponded very closely with the sample of Cheung et al. (25.5%) using the
same diagnostic test (MINI) and extremely similar patient profiles (Anglo-Saxon
dominant cultures i.e., New Zealand v. Australia). So too, both studies had similar
sample sizes (n=55 v. 56), demonstrated similar levels of discriminant validity (AUC
79% v. 78.4%), and shared fair sensitivity (79% v. 71%) and specificity (71% v. 86%) at
their optimal cut-offs. However, the COPD severity in the population studied by
Cheung et al. was not reported, raising the question as to whether this may have
affected prevalence rates which would ultimately impact on sensitivity and specificity
scores. Cheung et al. acknowledged their optimal cut-off was ‘unusually low’ and
further replication of their results was therefore warranted. The fact that we were
unable to replicate their results now casts doubt over their suggestion of a HADS-A
cut-off of ≥4 for COPD patients. Further attempts to replicate the results of Cheung et
al. are needed to clarify this matter.

Contrary to Nowak et al. who suggested the HADS-D provided poor discriminant
validity for COPD patients (AUC 66.2%), our results suggested its discrimination was

58

excellent (AUC 94.8%). Even with their optimal cut-off ≥6, Nowak et al. observed a
borderline sensitivity/specificity of 62.1/62.6% contrasting with our optimal cut-off ≥7
achieving 100.0/78.7%, and improving even further with removal of Question 4 and
lowering the cut-off to ≥5 yielding 100.0/83.0%. There are many possibilities why we
were unable to replicate the results of Nowak et al., including vastly differing sample
sizes (n=259 v. 56), differing prevalence of major depression (16.1% vs 11.2%), use of
the German v. English version of the HADS, differing cultures and use of pre-diagnosed
depression based on medical records subsequently confirmed by the patient’s
physician v. current diagnosis confirmed by a psychologist using a structured clinical
interview.

Despite the HADS being created to avoid somatic symptom overlap with anxiety and
depression in medical patients, the continued use of HADS with chronic diseases
remains contentious as a variety of cut-offs have been suggested differing from
optimal cut-off scores suggested for the general patient population e.g. HADS-D ≥4 in
coronary heart disease (118) and HADS-D ≥11 in end-stage renal disease (119). Given
that the discriminant validity of the HADS has only been tested in COPD populations
three times with divergent results, the recommendation of using this screening tool in
international management guidelines remains contentious. More population-specific
tools, such as the Geriatric Anxiety Inventory and COPD Anxiety Questionnaire
(German: CAF), may be preferable (120, 121). However, Cheung et al. investigated the
Geriatric Anxiety Inventory as another alternative measure for use with COPD patients
but found it no more useful than the HADS, and to the best of our knowledge the CAF
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has yet to be translated and validated for use in English and we are unaware of any
others for COPD.

The second aim of our study was to examine the discriminant validity of the BDI-II and
BAI as viable alternatives to the HADS for use with patients diagnosed with COPD. The
BDI-II

demonstrated

excellent

discriminant

validity

and

very

similar

sensitivity/specificity to the HADS-D. Question 21 did not discriminate between those
with and without clinical depression. However, its removal only marginally improved
the validity of optimal cut-offs (J = 0.77 vs 0.79). Therefore we see little value in
unnecessarily modifying the BDI-II for use with COPD patients. Likewise, the BAI
demonstrated similar discriminant validity to the HADS-A. However, given the shorter
length of the HADS (14 items combined) compared to the BDI-II and BAI (42 items
combined) and the free use of the former, versus cost per test of the latter, there may
be limited advantage of using the Beck inventories over the HADS.

The relatively modest sample size of stable COPD patients in our study increases the
probable error of our prevalence estimates. However, they were highly consistent with
previous estimates, giving us some reassurance that they are reasonably
representative. It is possible our study suffered selection bias; patients suffering
poorer mental health may have been more motivated to participate, thus inflating our
prevalence estimates. Fortunately, we achieved a consent rate of 55% implying our
data represent the majority of our sample, thereby reducing this potential for sampling
error. Another potential limitation is that we did not exclude participation in
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pulmonary rehabilitation as a possible confounder, which previous evidence suggests
can be effective for reducing anxiety and depression in COPD patients (25, 122).
Cheung et al. and Nowak et al. also failed to control for this, as such future studies
should ensure that pulmonary rehabilitation is treated as a covariate.

4.7

Clinical implications

Since Question 4 from the HADS-D appears to be a universal symptom of COPD
patients and our data suggests the removal of this question and lowering the cut-off to
≥ 5 provides superior sensitivity and specificity, we recommend this course of action
when using the HADS-D specifically with people diagnosed with COPD. As the HADS-A
provided fair sensitivity and specificity and no items appeared to overlap with the
symptomatology of COPD we recommend retaining the standard cut-off point of ≥8 for
the HADS-A until such time as future studies suggest otherwise. Our results therefore
support current guidelines of routine use of the HADS as a screening instrument for
COPD patients, retaining the traditional HADS-A cut-off score of ≥8 whilst removing
Question 4 for the HADS-D and using a lower cut-off score of ≥5.

Our investigation into the validity of screening tools for use in a clinical setting further
highlights the importance of appropriate follow-up measures for those that screen
positive. However, due to the restrictive time-frame of these measures, it is possible
that patients may feel depressed without being flagged as suffering from clinical levels
and should therefore also be considered for follow-up. Our study found that those
clinically diagnosed with depression via the MINI and also screened as having
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depression symptomatology in both the HADS-D and BDI-II had significantly higher
mean scores than those that did not screen positive. Whilst the proportion of true
positive to false positive cases was too small to be able to draw any definitive
conclusions, another avenue for future research which has very important implications
for targeted screening and treatment may be to investigate the demographic and
physiological differences (e.g. FEV1, 6MWT, number of exacerbations) in COPD
patients which may help to distinguish between these two subgroups.
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CHAPTER FIVE

A randomised controlled trial investigating the efficacy of cognitive behavioural
therapy on the mental health of people with chronic obstructive pulmonary disease:
the ‘Breathing New Life’ study

This manuscript was submitted for publication in the journal Trials on the 21 st of May
2017 and is still currently under review.

Tina Phan, Owen Carter, Grant Waterer, Li Ping Chung, Maxine Hawkins, Cobie Rudd,
Mel Ziman, Johnny Lo & Natalie Strobel. A randomised controlled trial investigating the
efficacy of cognitive behavioural therapy on the mental health of people with chronic
obstructive pulmonary disease: the ‘Breathing New Life’ study. Trials. (Submitted for
review on 21 May 2017)
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5 Study rationale

The following chapter (Study Three) seeks to investigate the efficacy of cognitive
behavioural therapy (CBT) in addition to usual care for the treatment of anxiety and
depression in people living with chronic obstructive pulmonary disease (COPD),
compared to usual care alone. As investigational studies have commonly reported
participants’ lack of transport, lack of time and illness as barriers to recruitment and
successful completion, a novel self-management resource was developed in the format
of a DVD with accompanying manual to overcome these issues. A randomised
controlled trial was conducted to investigate the efficacy of CBT delivered via a
traditional group therapy format with a reduced number of sessions (CBT) or a homebased self-management DVD format (DVD) in reducing psychological symptomatology.
The secondary aim was to investigate the efficacy of these CBT interventions to
improve health-related quality of life (HRQoL) relative to usual care. It was
hypothesised the CBT and DVD groups would have better mental health and HRQoL
outcomes after 12 months compared to the usual care alone group, with the DVD
group likely to have higher treatment compliance due to the nature of the resource.

The study was a randomised controlled trial comparing two half-day group face-to-face
CBT sessions with a one-hour telephone booster session and the six week ‘Breathing
New Life’ home-based self-management CBT learning resource (DVD) and
accompanying manual, relative to usual care alone. Results of the study indicate there
were no significant changes over time in anxiety, depression or HRQoL between any
for our COPD study groups.
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CHAPTER SIX

A qualitative investigation of the facilitators and barriers for people with chronic
obstructive pulmonary disease to participate in cognitive behavioural therapy

This manuscript was submitted for publication into Journal of Health Psychology on the
13th of November 2017 and is currently under review.

Tina Phan, Owen Carter, Grant Waterer, Li Ping Chung, Maxine Hawkins, Cobie Rudd &
Natalie Strobel. A qualitative investigation of the facilitators and barriers for people
with chronic obstructive pulmonary disease to participate in cognitive behavioural
therapy. Journal of Health Psychology. (Submitted for review on 13 November 2017).
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6 Study rationale

Cognitive Behavioural Therapy (CBT) is a promising treatment option for people with
COPD suffering from anxiety and depression, but many investigative studies report low
recruitment and high attrition rates. The following chapter (Study Four) seeks to
investigate the facilitators and barriers to successful completion of CBT delivered via
face-to-face groups (CBT) or DVD (DVD) as reported in the previous chapter (Study
Three), with the aim to improve future recruitment and retention.

This is the first known qualitative study undertaken to specifically investigate the
facilitators and barriers to uptake and completion of CBT in people with COPD. Indepth interviews were conducted with a subset sample of people from the wider
Breathing New Life study cohort.

Transcriptions were

analysed

using a

phenomenological approach. Key facilitators for traditional face-to-face group CBT
included the social interaction, whilst for both modalities the ability to identify with
other people suffering from COPD was important. Some DVD participants lacked the
technical skills required to actively engage with technology and the accompanying
manual.
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CHAPTER SEVEN

7 GENERAL DISCUSSION

7.1

Discussion

This thesis was originally undertaken in response to a need suggested in the literature
for greater accessibility to psychological treatment options for anxiety and depression
for people living with chronic obstructive pulmonary disease (COPD). Building upon a
promising body of literature demonstrating the efficacy of traditional face-to-face
group cognitive behavioural therapy (CBT) for people with COPD, a novel, home-based
self-management CBT resource in the form of a DVD with accompanying manual, was
specifically developed for people with COPD. This resource was developed using
considerable expertise from a multi-disciplinary team, including respiratory physicians,
psychologists, physiotherapists, nurses, health consumer representatives and COPD
patients themselves. A randomised controlled trial methodology was devised and
undertaken to test the efficacy of this novel intervention compared to CBT delivered as
shortened group sessions and care as usual defined as treatment prescribed by
participants’ GPs. However, the study failed to establish the efficacy of either format of
CBT to improve anxiety, depression or health-related quality of life (HRQoL). A number
of possible explanations exist for why this thesis failed to replicate previous findings
that demonstrated the efficacy of CBT for this cohort. Some explanations have already
been discussed in Chapter Five but there are others that also need to be acknowledged
in the context of this thesis. Given that the cognitive behavioural paradigm is well
established in psychological science as an effective theoretical framework for the
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treatment of anxiety and depression (123), it seems more likely that failure lay in the
treatment modalities. In previous studies that conducted face-to-face CBT sessions
with COPD populations, the number and length of sessions is highly variable, with the
number of sessions ranging from 1–12 with an average of six sessions conducted
between 90–120 minutes’ duration, with 120–720 minutes total time spent in sessions
and 0–6 follow-up phone calls provided (Appendix 2.1). However, the number of faceto-face CBT sessions in the present research was reduced to two 4.5 hour sessions,
plus a single follow-up 1 hour telephone call, to reduce the demand on participants.
Thus, the failure of the group CBT intervention to affect measurable improvements
may be due to an insufficient number of sessions; two sessions plus a telephone call
may not be enough for participants with COPD to establish measurable behavioural
changes that reduce anxious and depressive thoughts and feelings. More sessions may
be required but it is unclear exactly how many sessions would be optimal for a benefit
to be seen whilst simultaneously reducing the burden of attending face-to-face
sessions to prevent high drop-out rates in COPD participants. Furthermore, for those
with concomitant anxiety and depression, the question of how many sessions are
optimally required to treat both psychological conditions must also be considered, as
the brief CBT intervention used in this thesis may not simply have been enough.

The home-based self-management CBT intervention on DVD with accompanying
manual was also developed to reduce the need to travel and was based upon two
previous studies in people with COPD demonstrating positive mental health outcomes
from CBT delivered via an audio CD and self-help manual, and via a manual alone (35,
38). However, the present research was unable to demonstrate the efficacy of this six
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week, self-paced, CBT intervention on DVD with accompanying manual. One possible
reason why the home-based self-management intervention did not work may have
been due to the lack of interactive support. Both studies which found a significant
improvement on anxiety and depression had telephone support in addition to the selfmanagement resources. However, the DVD resource investigated in this thesis had no
additional telephone coaching supplied—follow-up phone calls were only undertaken
to monitor compliance. Self-management CBT may require additional personal support
when

delivered

to

people

with

COPD.

Further

investigation

of

self-management CBT resources in people with COPD are clearly required and
should aim to compare the delivery of home-based self-management CBT resources
whilst systematically varying telephone support to investigate whether this is the case.

It is possible that the study was statistically underpowered due to its sample size.
Increasing the sample size would undoubtedly have improved the chance of
producing a statistically significant result but as previously discussed in Chapter Five,
this difference would have been small (one point mean difference between groups on
the BAI and BDI-II) raising the question whether the difference would translate into
any practical, clinical meaningfulness. This highlights the importance of developing an
intervention to achieve clinically meaningful outcomes so that the patient population
directly benefits from noticeable improved symptomatology. It is also entirely possible
that only two published manuscripts describing successful self-management CBT
interventions for people with COPD exist so far due to publication bias, evident where
scientific journals are more likely to report statistically significant results and less likely
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to publish results of studies with null hypotheses (124). Consequently, publication bias
may also deter researchers from submitting their manuscripts with null hypotheses.
Thus it is conceivable that other studies also found a lack of significant clinical
improvements to psychological symptomatology using self-management CBT
resources and this thesis was not alone in that conclusion, potentially explaining why a
positive effect was not detected because this method of delivering CBT is not
efficacious.

Although no measurable benefit was detected for either of the CBT interventions used
in the randomised controlled trial, the qualitative results from Study Four (Chapter Six)
suggest participants perceived some value. This dissonance raises the question as to
why their perceived value did not translate to quantifiable improvements in
symptomatology scores. One possible explanation is that despite the interviewer’s
best efforts to establish rapport and pursue in-depth lines of enquiry, the interviewed
participants potentially remained too polite to complain about the interventions and
the interviews suffered from a degree of socially desirable response bias. A second
explanation is that the interviews suffered from response bias with participants who
found the intervention helpful more likely to consent to participate in the interviews
than those who found it unhelpful. Fortunately, a comparison of interviewed versus
non-interviewed participants’ quantitative anxiety and depression measures is
possible. If the former explanation was the case, then it would be expected that
interviewed participants’ scores would differ little from non-interviewed participants’
scores. If the latter explanation is true then it would be expected that interviewed
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participants’ scores would differ significantly from those not interviewed. As it turns
out, interview participants had slightly, but significantly, lower anxiety scores and
significant and substantially lower depression scores than their non-interviewed
counterparts six months after the interventions—the time when the interviews took
place (Table 7.1). These data support the theory that there was selection bias for the
interviews, thereby providing a compelling explanation for the discord between the
quantitative and qualitative results of the present dissertation. To overcome this
limitation, future research would benefit from further stratifying the interview sample
into groups of participants who objectively improved their psychological
symptomatology.

Table 7.1 Independent t-tests comparing 6-month post-intervention Beck Anxiety
Inventory (BAI) and Beck Depression Inventory (BDI-II) mean scores of participants
interviewed vs. not-interviewed
Measure

Group

Mean ± SD

Mean difference

p-value

BAI

Interviewed
Not-interviewed

15.56 ± 8.88
16.31 ± 12.00

0.752

0.858

BDI-II

Interviewed
Not-interviewed

13.44 ± 8.16
21.60 ± 11.49

8.152

0.046

Another possible cause of selection bias which future research would benefit from
addressing is the differing stages of behaviour change in participants. The benefits
reported by the subset of participants interviewed may not accurately reflect the
opinions of all involved in the Breathing New Life study as those interviewed may have
entered the study at a stage receptive to long-term behaviour change. Thus, as
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outlined in the Transtheoretical model of behaviour change (125), these participants
believed the CBT interventions helped them because they were open to the possibility.
However, those not interviewed and the vast majority of participants may have
inversely been in the ‘pre-contemplation’ stage with either no-to-little intention to
change before entering the study or the ‘action’ stage where active efforts to change
occurred but participants were unable to maintain these new positive behaviours and
instead relapsed into a previous stage (125). Future research would benefit from
building individual capacity for COPD participants to engage in their care by actually
asking whether they are ready for change before involvement in CBT and investigating
how best to support participants once enrolled, to maximise mental health outcomes.

Due to the convenient nature of the DVD resource, it was hypothesised that
compliance rates in the DVD group would be higher than those in the CBT group.
However, comparable compliance rates were found that reinforced the opinions
reported by participants in Study Four (Chapter Six) that the CBT treatments were
sufficient in terms of setting, delivery, content, duration and number of sessions which
were hypothesised as potential barriers. People with COPD appear to enjoy CBT and
find it is a useful treatment approach once engaged. Recruiting participants in the first
place remains a great hurdle. Findings from Study Four (Chapter Six) suggest that the
best way to target this type of therapy to COPD populations is to describe the benefits
of better breathing control skills gained and the importance of learning and benefitting
from shared experiences with their peers.
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The present research also specifically investigated the determinants for concomitant
anxiety and depression in people with COPD in order to build a holistic picture of risk
factors for this population which are currently lacking. As mentioned previously, it is
somewhat surprising that the literature investigating risk factors has primarily treated
the morbidity and mortality attributed to anxiety and depression independently, given
that 22–48% of people with COPD are estimated to suffer from concomitant
psychological symptomatology (61). The finding that people with COPD at a younger
age are at greater risk of both anxiety and depression makes implicit sense. Receiving a
diagnosis of an irreversible, progressive lung disease at a younger age would be more
distressing than receiving the same diagnosis at an older age due to the life-long
implications and greater loss potentially perceived by people of younger age. It would
be advantageous for clinicians to be particularly mindful of their patient’s mental
health when dealing with those diagnosed with COPD at a relatively younger age
compared to most other patients.

Lastly, findings of this thesis support the use of screening tools for psychological
symptomatology in people with COPD. The commonly used screening measures in
people with COPD tested for this thesis all demonstrated good discriminant validity
with a structured clinical interview, with minor adjustments to the BDI-II and the
Hospital Anxiety and Depression Scale (HADS) depression subscale further improving
sensitivity and specificity. However, our results for the HADS remain equivocal as they
contrasted with the two previous studies investigating this tool in people with COPD.
Furthermore, the Beck inventories have yet to be validated for use in people with
COPD despite their popularity as screening tools in COPD literature. Replication is the
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cornerstone of the scientific method and future validation studies are clearly required
to provide more clarity to this area.

7.2

Thesis limitations

The strengths and limitations of individual studies presented in this thesis have been
discussed in each corresponding chapter. Thus, this section will focus on research
limitations applicable to the greater research findings. As previously mentioned, some
of the key strengths of this thesis are the use of a representative sample of people
with COPD, validated and popular outcome measures to screen for clinically significant
levels of anxiety and depression, and a randomised controlled design. Thus, readers
can be assured the study findings are based on sound methodology. However, due to
the nature of the study topic, it is possible this sample of people with COPD suffered
from selection bias with those who were not anxious or depressed less likely to
volunteer to participate or relate to the treatment options, or see the need for
continued follow-up. There are limited solutions to control for this problem, thus
readers should bear this in mind when interpreting the results of this thesis.

Some may also argue the use of screening tools to examine the prevalence of clinically
significant levels of anxiety and depression distress levels in our COPD cohort limits
conclusions drawn due to their inability to provide a psychiatric diagnosis that comes
from a structured clinical interview. However, whilst a diagnosis from a structured
clinical interview that meets The Diagnostic and Statistical Manual of Mental Disorders
or the International Classification of Diseases and Related Health Problems criteria is
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considered gold standard, the use of these measures can be a costly and timeintensive endeavour, hindering recruitment timelines. Study Two (Chapter Four)
established the discriminant validity of the Beck inventories to the Mini
Neuropsychiatric Interview and found they produced adequate sensitivity and
specificity, thus providing confidence that the use of these screening tools was
appropriate for our cohort. Furthermore, the Beck inventories are commonly used in
previous studies and our use of these tools facilitates easy comparisons. Future studies
may prefer to use structured clinical interviews to address these concerns.

The randomised controlled trial (RCT) conducted for this thesis was based upon
literature that seemed clear and consistent on the efficacy of brief interventions. As
such, the study was based upon the best available evidence. The fact that this thesis
was unable to replicate previous findings is useful science as it suggests the extant
literature is less robust than previously thought. It may be seen as a limitation that no
pilot study was conducted to collect preliminary data and information to adapt the CBT
interventions for optimal success in the RCT. Conducting the qualitative investigation
into the barriers and facilitators to CBT faced by people with COPD after the
interventions were carried out also limited the range of data collected and subsequent
opportunity to shape and inform the RCT for this dissertation. It would be of great
benefit to ensure these factors are investigated prior to conduction of future CBT
intervention studies to maximise study design for optimal success.
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7.3

Concluding comments

There is little doubt that anxiety and depression are common comorbidities in people
with COPD which contribute to greater morbidity and mortality in an already
vulnerable population. Globally, findings from this thesis confirm the importance of
routine screening and treatment for anxiety and depression in people living with
COPD, especially those diagnosed at a younger age and without prior psychological
medical history. The HADS is recommended as a short, free and validated tool for such
screening but clinicians might consider a simple adjustment to the HADS depression
subscale, as outlined in Chapter Four. People with COPD tend to be sceptical about the
potential benefit for CBT to improve their lives. However, CBT can be promoted to this
cohort by emphasising that it is a non-pharmacological approach to symptom
reduction, techniques are taught to control breathing and support can be gained from
sharing experiences with other people suffering from COPD. It is the author’s hope
that the research conducted as part of this thesis will eventually contribute to clear
mental health recommendations in global guidelines for clinicians to refer to in order
to improve the quality of life of people living with COPD.
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